We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




HPV Tests Useful in ASCUS Cases

By HospiMedica staff writers
Posted on 26 Jan 2006
When a Pap test result is classified as atypical squamous cells of undetermined significance (ASCUS), a test for the human papillomarvirus (HPV) may be the best way to proceed, according to a new study reported in the January 18, 2006, issue of the Journal of the National Cancer Institute,

An HPV test would help a doctor to decide whether or not the patient should have more invasive testing. More...
Conservative management with additional testing or immediate colposcopy were both shown to be less cost-effective.

The study involved 3,488 women with ASCUS results, who were randomly assigned to colposcopy, HPV triage followed by colposcopy if an oncogenic virus was found, or conservative management based on repeating the Pap test, with a referral to colposcopy if the patient had high-grade intraepithelial lesions.

Although the least costly stratety turned out to be conservative management with only one repeat Pap test, this method was found to detect the fewest number of precancer cases. While adding additional tests improved detection, it was less cost-effective. An immediate referral of the patient for colposcopy was shown to be cost-effective only if that procedure and a subsequent biopsy were assumed to be 100% sensitive.

In contrast, testing for HPV was both lest costly and a better predictor of precancer and cancer cases than either conservative management or immediate colposcopy.

The researchers, from the Duke Center for Clinical Health Policy Research (Durham, NC, USA; www.dukehealth.org), said that using the same money to reduce health-case disparities and to extend screening to under-screened groups "might have a greater impact on cervical cancer mortality than applying those resources to HPV triage of ASCUS.”






Related Links:
Duke Center

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Monitor/Defibrillator
Zenix
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.